Navigating Treatment Challenges in HER2+ Breast Cancer

EP: 1.Evolving HER2+ Breast Cancer Care: Neo-Adjuvant Strategies and Treatment Goals

EP: 2.Neoadjuvant Approaches in HER2+ Breast Cancer

EP: 3.HER2+ Breast Cancer: Anthracycline Considerations

EP: 4.Subcutaneous HER2+ Breast Cancer Treatment Trends

EP: 5.Adjuvant Strategies in HER2+ Brest Cancer: Timing and Tailoring

EP: 6.Evolving Strategies in Adjuvant HER2+ Breast Cancer

EP: 7.Exploring Therapeutic Avenues in HER2+ Breast Cancer

EP: 8.Metastatic HER2+ Breast Cancer: Current Strategies and Ongoing Trials

EP: 9.Navigating Second-Line Choices in HER2+ Breast Cancer

EP: 10.Decoding HER2+ Breast Cancer: Challenges in Brain Metastases

EP: 11.Navigating HER2+ Brain Metastases: Emerging Insights

EP: 12.HER2+ Breast Cancer Treatment Dynamics and Challenges

Now Viewing

EP: 13.Navigating Treatment Challenges in HER2+ Breast Cancer

EP: 14.Insights and Challenges in Advancing HER2+ Breast Cancer Care

This is a video synopsis/summary of a Peer Exchange involving Joyce O’Shaughnessy, MD; Priyanka Sharma, MD; Claudine Isaacs, MD; Heather McArthur, MD; and Hope S. Rugo, MD, FASCO.

The discussion focuses on third-line treatment decisions for patients with HER2-positive breast cancer post–T-DM1 and tucatinib exposure. Sharma anticipates evolving challenges with emerging data and considers factors such as CDK4/6 inhibitors. O’Shaughnessy and McArthur highlight the complexity of sequencing, emphasizing the lack of comprehensive data and exploring the intricacies of antibody-drug conjugates (ADCs). McArthur discusses the challenges and potential of novel ADCs, collaborations, and combinations with checkpoint blockade. The absence of clear sequencing guidelines underscores the importance of patient-centered shared decision-making, considering factors such as toxicity profiles and clinical characteristics.

Video synopsis is AI-generated and reviewed by OncLive^® editorial staff.